United States - English - NLM (National Library of Medicine)

us worldmeds, llc - tegaserod (unii: 458vc51857) (tegaserod - unii:458vc51857) - zelnorm is indicated for the treatment of adult women less than 65 years of age with irritable bowel syndrome with constipation (ibs-c). limitations of use - the safety and effectiveness of zelnorm in men with ibs-c have not been established [see clinical studies (14)] . zelnorm is contraindicated in patients with: - a history of myocardial infarction (mi), stroke, transient ischemic attack (tia), or angina [see warnings and precautions (5.1)] - a history of ischemic colitis or other forms of intestinal ischemia [see warnings and precautions (5.2)] - severe renal impairment (egfr< 15 ml/min/1.73 m2 ) or end-stage renal disease [see use in specific populations (8.6)] - moderate and severe hepatic impairment (child-pugh b or c) [see use in specific populations (8.7)] - a history of bowel obstruction, symptomatic gallbladder disease, suspected sphincter of oddi dysfunction, or abdominal adhesions [see adverse reactions (6.2)] - hypersensitivity to tegaserod [see adverse reactions (6.2)] risk summary availabl

United States - English - NLM (National Library of Medicine)

us worldmeds, llc - dantrolene sodium (unii: 287m0347ev) (dantrolene - unii:f64qu97qcr) - dantrolene sodium 20 mg in 60 ml - revonto (dantrolene sodium for injection) is indicated, along with appropriate supportive measures, for the management of the fulminant hypermetabolism of skeletal muscle characteristic of malignant hyperthermia crises in patients of all ages. revonto should be administered by continuous rapid intravenous push as soon as the malignant hyperthermia reaction is recognized (i.e., tachycardia, tachypnea, central venous desaturation, hypercarbia, metabolic acidosis, skeletal muscle rigidity, increased utilization of anesthesia circuit carbon dioxide absorber, cyanosis and mottling of the skin, and, in many cases, fever). revonto is also indicated preoperatively, and sometimes postoperatively, to prevent or attenuate the development of clinical and laboratory signs of malignant hyperthermia in individuals judged to be malignant hyperthermia susceptible. none.

United States - English - NLM (National Library of Medicine)

us worldmeds, llc - nadolol (unii: fen504330v) (nadolol - unii:fen504330v) - nadolol 20 mg - corgard (nadolol) is indicated for the long-term management of patients with angina pectoris. corgard (nadolol) is indicated for the treatment of hypertension, to lower blood pressure. lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. these benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the class to which this drug principally belongs. there are no controlled trials demonstrating risk reduction with corgard. control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. many patients will require more than one drug to achieve blood pressure goals. for specific advice on goals and management, see published guidelines, such as those of the national high blood pressure education pro

United States - English - NLM (National Library of Medicine)

us worldmeds, llc - lofexidine hydrochloride (unii: v47g1sdi1b) (lofexidine - unii:ui82k0t627) - lucemyra is indicated for mitigation of opioid withdrawal symptoms to facilitate abrupt opioid discontinuation in adults. none. risk summary the safety of lucemyra in pregnant women has not been established. in animal reproduction studies, oral administration of lofexidine during organogenesis to pregnant rats and rabbits caused a reduction in fetal weights, increases in fetal resorptions, and litter loss at exposures below that in humans. when oral lofexidine was administered from the beginning of organogenesis through lactation, increased stillbirths and litter loss were noted along with decreased viability and lactation indices. the offspring exhibited delays in sexual maturation, auditory startle, and surface righting. these effects occurred at exposures below that in humans [see animal data] . the background risk of major birth defects and miscarriage for the indicated population is unknown. all pregnancies carry some risk of birth defect, loss, or ot

United States - English - NLM (National Library of Medicine)

rebel distributors corp - mycophenolate mofetil (unii: 9242ecw6r0) (mycophenolic acid - unii:hu9dx48n0t) - mycophenolate mofetil 250 mg - cellcept is indicated for the prophylaxis of organ rejection in patients receiving allogeneic renal, cardiac or hepatic transplants. cellcept should be used concomitantly with cyclosporine and corticosteroids. cellcept intravenous is an alternative dosage form to cellcept capsules, tablets and oral suspension. cellcept intravenous should be administered within 24 hours following transplantation. cellcept intravenous can be administered for up to 14 days; patients should be switched to oral cellcept as soon as they can tolerate oral medication. allergic reactions to cellcept have been observed; therefore, cellcept is contraindicated in patients with a hypersensitivity to mycophenolate mofetil, mycophenolic acid or any component of the drug product. cellcept intravenous is contraindicated in patients who are allergic to polysorbate 80 (tween).

United States - English - NLM (National Library of Medicine)

us airways, inc - sodium monofluorophosphate (unii: c810jcz56q) (fluoride ion - unii:q80vpu408o) - fluoride ion 7.6 mg in 1 g - anticavity helps protect against cavities

New Zealand - English - Medsafe (Medicines Safety Authority)

roche products (nz) ltd - mycophenolate mofetil 250mg;   - capsule - 250 mg - active: mycophenolate mofetil 250mg   excipient: croscarmellose sodium gelatin magnesium stearate povidone pregelatinised maize starch - cellcept is indicated for the prophylaxis of solid organ rejection in adults receiving allogeneic organ transplants. cellcept is indicated for the prophylaxis of organ rejection in paediatric patients (2 to 18 years) receiving allogeneic renal transplants.

New Zealand - English - Medsafe (Medicines Safety Authority)

roche products (nz) ltd - mycophenolate mofetil 500mg (as 542 mg of the hydrochloride salt);   - powder for infusion - 500 mg - active: mycophenolate mofetil 500mg (as 542 mg of the hydrochloride salt)   excipient: citric acid polysorbate 80 sodium chloride - cellcept is indicated for the prophylaxis of solid organ rejection in adults receiving allogeneic organ transplants. cellcept is indicated for the prophylaxis of organ rejection in paediatric patients (2 to 18 years) receiving allogeneic renal transplants.

New Zealand - English - Medsafe (Medicines Safety Authority)

roche products (nz) ltd - mycophenolate mofetil 200 mg/ml;   - powder for oral suspension - 200 mg/ml - active: mycophenolate mofetil 200 mg/ml   excipient: aspartame citric acid colloidal silicon dioxide fruit mix flavour 274869 lecithin methyl hydroxybenzoate sodium citrate dihydrate sorbitol xanthan gum - cellcept is indicated for the prophylaxis of solid organ rejection in adults receiving allogeneic organ transplants. cellcept is indicated for the prophylaxis of organ rejection in paediatric patients (2 to 18 years) receiving allogeneic renal transplants.

New Zealand - English - Medsafe (Medicines Safety Authority)

roche products (nz) ltd - mycophenolate mofetil 500mg;   - tablet - 500 mg - active: mycophenolate mofetil 500mg   excipient: croscarmellose sodium magnesium stearate microcrystalline cellulose opadry lavender y-5-10272-a povidone - cellcept is indicated for the prophylaxis of solid organ rejection in adults receiving allogeneic organ transplants. cellcept is indicated for the prophylaxis of organ rejection in paediatric patients (2 to 18 years) receiving allogeneic renal transplants.